Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

Core Points - *ST Changyao has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false financial reporting [1] - Investors who purchased shares between March 30, 2019, and April 29, 2024, may have the opportunity to claim compensation if they sold or still hold shares at a loss after April 30, 2024 [1] Summary by Sections Company Investigation - The CSRC has decided to initiate a case against *ST Changyao due to allegations of false records in periodic financial reports [1] Investor Compensation - According to lawyer Xu Jin, investors can file civil compensation lawsuits without prior procedures due to new judicial interpretations regarding securities false statements [1] - Compensation claims may include losses from investment differences, stamp duty, and commission losses [1] Claim Conditions - Investors must have bought shares between March 30, 2019, and April 29, 2024, and must have sold or still hold shares at a loss after April 30, 2024, to qualify for claims [1] - Required materials for claims include a copy of the ID, confirmation of securities account opening, and transaction records stamped by the brokerage [1]

Market Overview - During the week of November 10 to November 14, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index closing at 3990.49 points, down 0.18% for the week, the Shenzhen Component Index at 13216.03 points, down 1.40%, and the ChiNext Index at 3111.51 points, down 3.01% [2] - Over 56% of individual stocks experienced gains during the week, with 170 stocks rising over 15% and 23 stocks declining over 15%. Sectors such as textiles, retail, beauty care, biomedicine, and food and beverage saw increases, while communication, electronics, computers, machinery, and defense industries faced declines [2] Top Performing Stocks - Huasheng Lithium Battery (688353.SH) led the weekly gainers with a remarkable 79.61% increase, followed by Haike Xinyuan (301292.SZ) at 71.38%. Other notable gainers included Jindike (688670.SH), Furui Shares (002083.SZ), Renmin Tongtai (600829.SH), and Dongbai Group (600693.SH), all exceeding 61% in weekly gains [4] - The stock price of Huasheng Lithium Battery reached a historical high, closing at 139.20 yuan, with a total market capitalization of 22.2 billion yuan. The stock has seen a cumulative increase of over 172% from November 5 to November 14 [5][6] Huasheng Lithium Battery Details - Huasheng Lithium Battery specializes in the research, production, and sales of lithium battery electrolyte additives, with a significant market presence in China and exports to Japan, South Korea, the United States, Europe, and Southeast Asia. The company ranked first in domestic market share for lithium-ion battery electrolyte additives from 2018 to 2020 [5] - The recent price surge in the electrolyte industry has driven the prices of additive products higher, with battery-grade vinyl carbonate rising from 48,800 yuan/ton to 57,000 yuan/ton in October, and a significant daily increase of 8.13% to 66,500 yuan/ton on November 10 [5][6] Underperforming Stocks - *ST Changyao (300391.SZ) was the worst performer of the week, with a decline of 33.62%. Other stocks such as Haitan Shares (603759.SH), Degute (300950.SZ), and Bangji Technology (603151.SH) also saw declines exceeding 17% [9] - The company is under investigation by the China Securities Regulatory Commission for suspected financial fraud, which may lead to forced delisting if significant violations are confirmed [10][11] *ST Changyao Company Overview - *ST Changyao operates in the pharmaceutical industry, focusing on the production and sales of traditional Chinese medicine pieces, medicinal capsules, and medical logistics. The company has faced challenges, including a warning of potential delisting due to negative net profits over the past three years [10][11] - The company reported a revenue of 105 million yuan for the first three quarters of 2025, a year-on-year increase of 4.4%, but a net loss of 210 million yuan, a decline of 15.89% [12]

Core Viewpoint - *ST Changyao is embroiled in a financial fraud scandal, facing a formal investigation by the China Securities Regulatory Commission (CSRC) due to suspected false reporting of financial data, which could lead to mandatory delisting if deemed a major violation [1][2]. Group 1: Financial Fraud Investigation - The investigation focuses on the authenticity of *ST Changyao's financial data, highlighting severe deficiencies in its information disclosure quality and internal control systems [2]. - The company has already been warned of delisting risks due to a negative net asset value reported for the fiscal year 2024 [2]. Group 2: Deteriorating Operations - Since entering the pharmaceutical industry in 2020 and fully transforming in 2022, *ST Changyao has not achieved expected growth, with revenue plummeting from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [3]. - The company's net profit has been negative for consecutive years, with net assets reported at -433 million yuan by the end of 2024, worsening to -643 million yuan by the end of Q3 2025 [3]. - Operating cash flow has been negative for three consecutive years, raising significant doubts about the company's ability to continue as a going concern [3]. Group 3: Legal and Financial Risks - *ST Changyao is facing multiple legal challenges, with 140 lawsuits involving a total amount of 1.878 billion yuan, which is 434% of its net assets, indicating governance issues and compliance failures [4]. - The company has 1.106 billion yuan in interest-bearing liabilities, with 390 million yuan overdue, leading to severe liquidity issues [4]. - A significant portion of the company's bank accounts, 67.7%, are frozen, impacting daily operations and cash flow management [4]. Group 4: Conclusion - *ST Changyao is undergoing its most severe test since its listing, facing a crisis that requires urgent resolution of debts and regulatory concerns to maintain its position in the capital market [5].

New Stock Issuance - Cash option declaration period for Hangzhou Steam Turbine (200771) is from November 19 to November 25, 2025[1] - Acquisition request period for Hailianxun (300277) is from November 12 to November 18, 2025[1] Trading Alerts - Severe abnormal fluctuation reported for Haike Xinyuan (301292) on November 11, 2025[1] - Abnormal fluctuation noted for ST Yuancheng (603388) on November 11, 2025[1] Company Announcements - Announcement for Tianji Co., Ltd. (002759) on November 13, 2025[1] - Announcement for Huatong Technology (688109) on November 13, 2025[1] Other Notable Events - ST Meigu (000615) reported on November 13, 2025[1] - ST Zhongdi (000609) reported on November 13, 2025[1]

New Stock Issuance - The stock code 300277 (Hai Lian Xun) has a subscription period for acquisition rights from November 12 to November 18, 2025[1] - Stock code 688353 (Hua Sheng Lithium) reported severe abnormal fluctuations on November 11, 2025[1] - Stock code 603122 (He Fu China) has an announcement dated November 8, 2025[1] Trading Alerts - Stock code 601888 (China Zhong Mian) has an announcement dated November 12, 2025[1] - Stock code 600537 (Yi Jing Guang Dian) has an announcement dated November 12, 2025[1] - Stock code 688028 (Wo Er De) has an announcement dated November 12, 2025[1] Abnormal Fluctuations - Stock code 600815 (Xia Gong Co.) reported abnormal fluctuations on November 6, 2025[2] - Stock code 603557 (ST Qi Bu) reported abnormal fluctuations on November 7, 2025[3] - Stock code 002478 (Chang Bao Co.) reported abnormal fluctuations on November 7, 2025[3]

证券代码：300391 证券简称：*ST 长药 公告编号：2025-098 长江医药控股股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、股票交易异常波动情况 5、经问询，本次股票异常波动期间，公司控股股东、实际控制人未发生买 卖公司股票的行为。 6、公司不存在需披露业绩预告的情况。 7、目前公司日常经营管理工作没有显著变化。 三、不存在应披露而未披露信息的说明 长江医药控股股份有限公司（以下简称"公司"）股票于2025年11月10日、 2025年11月11日连续2个交易日内日收盘价格跌幅偏离值累计-34.98%，根据《深 圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情形。敬请广大 投资者注意投资风险。 二、公司关注并核实情况说明 针对本次公司股票交易异常波动，公司董事会就相关事项进行了核实与自查， 具体情况如下： 1、公司前期披露的信息目前不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、2025年11月7日，公司收到中国证券监督管理委 ...

Core Points - *ST Changyao received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false financial reporting [1] - The company was previously known as Kangyue Technology and was listed on the Shenzhen Stock Exchange in August 2014 [1] - *ST Changyao operates primarily in the pharmaceutical manufacturing sector and has a secondary focus on photovoltaic equipment [1] Financial Performance - For the first three quarters of 2025, *ST Changyao reported revenue of 105 million yuan, representing a year-on-year increase of 4.40% [1] - The company recorded a net loss attributable to shareholders of 210 million yuan, a decline of 15.89% compared to the previous year [1] Regulatory Risks - The company indicated that if the CSRC's administrative penalties confirm facts that fall under the major illegal circumstances as per the Shenzhen Stock Exchange's rules, it may face mandatory delisting [2]

Core Viewpoint - The recent addition of companies such as Bayi Steel and *ST Changyao to the investigation list by the China Securities Regulatory Commission (CSRC) has been perceived as a significant negative event, leading to sharp declines in their stock prices. The investigation is primarily due to violations related to information disclosure, with a notable percentage of affected companies facing operational difficulties and financial losses [1][3][4]. Group 1: Investigation Overview - As of November 10, 2023, a total of 60 companies have been investigated by the CSRC this year, with 90% of these cases related to suspected information disclosure violations [1][4]. - The latest companies added to the investigation list, Bayi Steel and *ST Changyao, both experienced a "limit down" in their stock prices on November 10, 2023, closing at 4.01 CNY per share (market cap 6.147 billion CNY) and 2.76 CNY per share (market cap 0.967 billion CNY) respectively [3][4]. Group 2: Financial Performance of Investigated Companies - Among the 60 companies under investigation, approximately 68.33% (41 companies) reported net losses in the first three quarters of 2023, indicating a concerning trend in financial performance [6][7]. - Notably, Bayi Steel recorded the largest net loss, amounting to approximately -572 million CNY, with other companies like Luohua Technology and *ST Muban also reporting significant losses exceeding 100 million CNY [7][8]. Group 3: Regulatory Actions and Penalties - Out of the 60 investigated companies, 25 have received penalties or pre-penalties from the CSRC, with 15 companies already facing fines [11][12]. - The penalties can be severe, with potential fines reaching up to 10 million CNY for administrative violations, and in serious cases, criminal charges may be pursued [4][12].

Core Points - *ST Changyao's stock price fell to 2.76 yuan, hitting a new low since July 3, 2022, with over 650,000 sell orders [1] - The company received a notice from the China Securities Regulatory Commission (CSRC) on November 7, 2025, regarding an investigation into suspected false financial reporting [1] - If the investigation confirms significant violations, the company may face mandatory delisting due to serious misconduct [1]